Evaluation of antimicrobial activity of ceftaroline against clostridium difficile and propensity to induce c. difficile infection in an in vitro human gut model

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1842-1849

  Baines, Simon D ^a   Chilton, Caroline H ^b   Crowther, Grace S ^b   Todhunter, Sharie L ^b   Freeman, Jane ^c   Wilcox, Mark H ^b,c  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Cephalosporins; Chemostat; MICs

Indexed keywords

CEFTAROLINE; CEFTRIAXONE; CYTOTOXIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BIOASSAY; CHEMOSTAT; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EXPOSURE; DRUG SCREENING; FECES; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTESTINE; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; SPORE GERMINATION;

CEPHALOSPORINS; CHEMOSTAT; MICS;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BACTERIAL TOXINS; CEFTRIAXONE; CEPHALOSPORINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; GASTROINTESTINAL TRACT; HEALTHY VOLUNTEERS; HUMAN ACTIVITIES; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL;

EID: 84880735854     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt107     Document Type: Article

References (42)

1. Ellames D, Wilcox MH, Fawley W et al. Comparison of risk factors and outcome of cases of Clostridium difficile infection due to ribotype 027 versus other ribotypes. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract K-605, p. 337. American Society for Microbiology, Washington, DC, USA.
2. Kuijper EJ, Coignard B, Brazier JS et al. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill 2008; 13: pii1/418942.
3. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
4. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
5. HPA Clostridium difficile ribotyping network (CDRN) Annual Report 2010/ 2011. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317133396963 (18 February 2013, date last accessed).
6. Weigand PN, Nathwani D, Wilcox MH et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14.
7. Ghantoj SS, Sail K, Lairson DR et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74: 309-18.
8. Freeman J, Wilcox MH. Antibiotics and Clostridium difficile. Microbes Infect 1999; 1: 377-84.
9. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
10. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60.
11. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
12. Freeman J, Wilcox MH. Ureidopenicillins and risk of Clostridium difficile infection. J Antimicrob Chemother 2001; 47: 719.
13. Settle CD, Wilcox MH, Fawley WN et al. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998; 12: 1217-23.
14. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
15. Impallomeni M, Galletly NP, Wort SJ et al. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995; 311: 1345-6.
16. MacGowan AP, Feeney R, Brown I et al. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1997; 39: 537-41.
17. Baines SD, Saxton K, Freeman J et al. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58: 1062-5.
18. Saxton K, Baines SD, Freeman J et al. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 2009; 53: 412-20.
19. Chilton CH, Freeman J, Crowther GS et al. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. J Antimicrob Chemother 2012; 67: 951-4.
20. Crowther GS, Baines SD, Todhunter SL et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013; 68: 168-76.
21. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
22. Freeman J, Baines SD, Jabes D et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
23. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
24. Stubbs SL, Brazier JS, O'Neill GL et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-3.
25. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
26. Pletz MW, Rau M, Bulitta J et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-72.
27. Panagiotidis G, Bäckström T, Asker-Hagelberg C et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010; 54: 1811-4.
28. Forest Laboratories, Inc. Teflaro, Package Insert, 2010. http://www.frx.com/pi/Teflaro_pi.pdf (19 December 2012, date last accessed).
29. Freeman J, Wilcox MH. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2001; 47: 244-6.
30. Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-50.
31. Friedland HD, O'Neal T, Biek D et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56: 2231-6.
32. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: iii53-9.
33. Welling GW, Holtrop A, Slootmaker-van der Meulen C et al. Inactivation of ceftriaxone by faecal enzyme preparations during ceftriaxone treatment. J Antimicrob Chemother 1992; 30: 234-6.
34. Edlund C, Stark C, Nord CE. The relationship between an increase in b-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. J Antimicrob Chemother 1994; 34: 127-38.
35. Labia R, Barthelemy M, Peduzzi J et al. Overcoming enzymatic resistance in bacteria: impact on future therapy. J Int Med Res 1990; 18 Suppl 4: 48D-57D.
36. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064-73.
37. Rokosz A, Pawlowska J, Sawicka-Grzelak A et al. [ESBL-positive strains of the Bacteroides fragilis group isolated from patients at the regional hospital center in Plock (Poland)]. Med Dosw Mikrobiol 2004; 56: 245-53.
38. Kidwai M, Sapa P, Bhushan KR. Synthetic strategies and medicinal properties of b-lactams. Curr Med Chem 1999; 6: 195-215.
39. Vogel F, Ochs HR, Wettich K et al. Effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-acquired pneumonia. Clin Microbiol Infect 2001; 7: 376-9.
40. Denève C, Delomenie C, Barc MC et al. Antibiotics involved in Clostridium difficile-associated disease increase colonization factor gene expression. J Med Microbiol 2008; 57: 732-8.
41. Emerson JE, Stabler RA, Wren BW et al. Microarray analysis of the transcriptional responses of Clostridium difficile to environmental and antibiotic stress. J Med Microbiol 2008; 57: 757-64.
42. File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012; 55 Suppl 3: S173-80.